You just read:

Celator® Pharmaceuticals Announces Start of Clinical Study of CPX-351 in Acute Myeloid Leukemia Patients at High Risk for Induction Mortality

News provided by

Celator Pharmaceuticals, Inc.

Jul 14, 2015, 08:00 ET